Should regional anesthesia and pharmacological agents such as beta blockers and opiates be utilized in modulating pain response?
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D015760:Alfentanil; D000698:Analgesia; D000700:Analgesics / Q000378:metabolism / Q000627:therapeutic use; D000765:Anesthesia, Conduction; D000818:Animals; D002056:Burns / Q000503:physiopathology*; D016861:Cyclooxygenase Inhibitors; D005283:Fentanyl / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D008691:Methadone / Q000378:metabolism / Q000494:pharmacology; D008956:Models, Chemical; D009020:Morphine / Q000378:metabolism / Q000494:pharmacology; D009294:Narcotics / Q000627:therapeutic use*; D009407:Nerve Block; D010146:Pain / Q000503:physiopathology; D059408:Pain Management; D011433:Propranolol / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D016861:Cyclooxygenase Inhibitors; D009294:Narcotics; D015760:Alfentanil; D009020:Morphine; D011433:Propranolol; D008691:Methadone; D005283:Fentanyl